Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Return on Equity (2017 - 2025)

Historic Return on Equity for UroGen Pharma (URGN) over the last 7 years, with Q3 2025 value amounting to 1.58%.

  • UroGen Pharma's Return on Equity rose 57100.0% to 1.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.58%, marking a year-over-year increase of 57100.0%. This contributed to the annual value of 3.43% for FY2024, which is 21100.0% up from last year.
  • UroGen Pharma's Return on Equity amounted to 1.58% in Q3 2025, which was up 57100.0% from 2.22% recorded in Q2 2025.
  • UroGen Pharma's 5-year Return on Equity high stood at 26.16% for Q1 2022, and its period low was 15.18% during Q4 2024.
  • Over the past 5 years, UroGen Pharma's median Return on Equity value was 1.44% (recorded in 2022), while the average stood at 2.21%.
  • In the last 5 years, UroGen Pharma's Return on Equity soared by 275100bps in 2022 and then tumbled by -250700bps in 2023.
  • Quarter analysis of 5 years shows UroGen Pharma's Return on Equity stood at 5.55% in 2021, then skyrocketed by 126bps to 1.44% in 2022, then soared by 33bps to 1.91% in 2023, then plummeted by -896bps to 15.18% in 2024, then surged by 110bps to 1.58% in 2025.
  • Its Return on Equity stands at 1.58% for Q3 2025, versus 2.22% for Q2 2025 and 5.01% for Q1 2025.